drugset / Trial / NCT01077453

Letrozole in Preventing Breast Cancer in Healthy Postmenopausal Women at High Risk for Breast Cancer

NCT01077453

Phase 1 Completed 112 enrolled National Cancer Institute (NCI)
RandomizedParallel-groupDouble-blindPrevention

Summary

This randomized phase I trial studies the side effects and the best dose of letrozole in preventing breast cancer in healthy postmenopausal women at high risk for breast cancer. Chemoprevention is the use of drugs to keep breast cancer from forming or coming back. The use of letrozole may keep cancer from forming in healthy postmenopausal women at high risk for breast cancer.

Timeline

Start
2010-03
Primary completion
2014-06
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Letrozole Other / unclassified 0.25 mg Oral
Subject Letrozole Other / unclassified 1 mg Oral
Subject Letrozole Other / unclassified 2.5 mg Oral